A-Cof100 ml

A-Cof is a fixed-dose combination product indicated for the temporary symptomatic relief of cough, nasal and sinus congestion, sneezing, and rhinorrhea (runny nose) associated with the common cold, upper respiratory tract infections, and allergic rhinitis (hay fever).

• Established/labeled use: temporary relief of non-productive (dry) cough due to minor throat and bronchial irritation caused by the common cold or inhaled irritants.
• Established/labeled use: temporary relief of nasal congestion associated with the common cold, sinusitis, and allergic rhinitis.
• Established/labeled use: temporary relief of sneezing, itchy/watery eyes, and rhinorrhea associated with upper respiratory allergies (hay fever) and the common cold.

A-Cof treats symptoms only; it does not treat the underlying infection or its cause and is not a substitute for antibiotics when a bacterial infection is present.

Dextromethorphan + Pseudoephedrine + Triprolidine is typically formulated as an oral syrup. A common Bangladesh market strength per 5 mL is:

• Dextromethorphan Hydrobromide BP 10 mg
• Pseudoephedrine Hydrochloride BP 30 mg
• Triprolidine Hydrochloride BP 1.25 mg

Exact strengths and pack sizes may vary slightly between manufacturers; always check the product label of the specific brand dispensed.

A-Cof is a combination cough-and-cold preparation that brings together three agents with complementary actions: an antitussive (cough suppressant), a nasal decongestant, and a first-generation sedating antihistamine.

Dextromethorphan is a centrally acting, non-opioid antitussive chemically related to opioids but without significant analgesic or addictive properties at normal doses. Pseudoephedrine is a sympathomimetic amine that constricts swollen nasal blood vessels to relieve congestion. Triprolidine is a first-generation H1-antihistamine that reduces sneezing, itching, and rhinorrhea, and also contributes anticholinergic and sedating effects. Together, A-Cof is used as a single product to address the combination of symptoms typical of an upper respiratory infection or allergy rather than any single symptom alone.

A-Cof belongs to the therapeutic class of combination cough and cold preparations, combining three drug classes:

• Antitussive (cough suppressant) - dextromethorphan
• Nasal decongestant / sympathomimetic - pseudoephedrine
• First-generation (sedating) antihistamine - triprolidine

Dextromethorphan + Pseudoephedrine + Triprolidine combines three agents with distinct mechanisms of action:

Pharmacokinetics: All three components are well absorbed orally. Dextromethorphan is extensively metabolized in the liver via CYP2D6 to the active metabolite dextrorphan; pseudoephedrine is largely excreted unchanged renally with a half-life of roughly 5-8 hours (pH-dependent); triprolidine is hepatically metabolized with a half-life of approximately 3-5 hours. Onset of action for the decongestant and antihistamine effects is typically within 30-60 minutes.

A-Cof is for oral use only. Shake the syrup bottle well before each use. Use the measuring cup or spoon provided; do not use household spoons, as this can lead to inaccurate dosing. It may be taken with or without food; taking it with food may reduce stomach upset. Take the last dose a few hours before bedtime if daytime alertness is affected, though drowsiness from triprolidine can occur at any time of day. Do not exceed the recommended dose or frequency.

A-Cof has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Contraindicated. Concurrent use or use within 14 days of an MAOI can cause a hypertensive crisis (from pseudoephedrine) and serotonin syndrome (from dextromethorphan).
• Serotonergic drugs (e.g. SSRIs, SNRIs, triptans, linezolid, tramadol): increased risk of serotonin syndrome with the dextromethorphan component; use with caution and monitor for agitation, hyperthermia, and autonomic instability.
• CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine): can increase dextromethorphan plasma levels and the risk of adverse CNS effects.
• Other sympathomimetics/decongestants and antihypertensive agents (e.g. beta-blockers, methyldopa): pseudoephedrine can have additive cardiovascular stimulant effects and may reduce the antihypertensive effect of some blood-pressure medicines.
• CNS depressants and alcohol: the triprolidine component adds to sedation from alcohol, sedatives, hypnotics, and other CNS depressants.
• Other anticholinergic drugs: additive anticholinergic effects (dry mouth, urinary retention, constipation) with triprolidine.

Common side effects of A-Cof arise from its three components:

• From triprolidine (antihistamine): drowsiness/sedation (most common), dizziness, dry mouth, blurred vision, thickened bronchial secretions.
• From pseudoephedrine (decongestant): insomnia, nervousness, restlessness, palpitations, tachycardia, mild elevation in blood pressure, headache.
• From dextromethorphan (antitussive): generally mild at recommended doses; occasional dizziness, drowsiness, nausea, or gastrointestinal upset.

Less common effects include difficulty urinating, constipation, and excitability (particularly in children). Seek medical attention for signs of an allergic reaction (rash, swelling, difficulty breathing), rapid or irregular heartbeat, severe dizziness, or hallucinations.

Data specific to the fixed combination A-Cof in pregnancy and lactation are limited. As a general precaution, A-Cof should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use, particularly during the first trimester.

Pseudoephedrine has been associated in some studies with a small increased risk of gastroschisis when used in early pregnancy, and it may reduce milk supply during lactation. Sedating antihistamines such as triprolidine pass into breast milk and may cause drowsiness or irritability in a nursing infant. Because of these concerns, use during breastfeeding should be avoided unless a physician determines the benefit outweighs the risk.

Use A-Cof with caution in patients with:

• Hypertension, cardiovascular disease, or diabetes (due to the pseudoephedrine component's stimulant/pressor effects).
• Hyperthyroidism (pseudoephedrine may exacerbate symptoms).
• Narrow-angle glaucoma or symptomatic prostatic hypertrophy (anticholinergic effects of triprolidine) - see Contraindications.
• Asthma or chronic bronchitis/COPD with excessive secretions, as antihistamines can thicken bronchial secretions and impair clearance.
• Hepatic or renal impairment, which may slow clearance and increase drug levels.

A-Cof causes drowsiness; patients should avoid driving, operating heavy machinery, or performing hazardous tasks until they know how it affects them, and should avoid alcohol and other sedating medicines while taking it. Do not use for a persistent or chronic cough such as occurs with smoking, asthma, or emphysema, or when cough is accompanied by excessive phlegm, without consulting a physician. Do not exceed the recommended dose, as higher doses do not improve symptom control and increase the risk of side effects.

Overdose of A-Cof is a medical emergency. Symptoms may include marked drowsiness or, paradoxically, CNS excitation (especially in children) with hallucinations, tremor, seizures, extreme agitation and rapid heartbeat (from pseudoephedrine and dextromethorphan), severe hypertension, arrhythmias, hyperthermia, respiratory depression, and anticholinergic effects such as dilated pupils, dry flushed skin, and urinary retention (from triprolidine).

If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt home treatment; management is supportive and should be carried out in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Pediatric use: A-Cof is generally not recommended for children under 2 years of age due to the risk of serious and potentially fatal respiratory depression and other adverse effects associated with cough and cold combination products in young children. Use in children 2-6 years should only occur under direct medical supervision. Safety and efficacy in children under 6 years have not been well established for OTC use; consult a physician before use in this age group.

Elderly: Older adults may be more sensitive to the anticholinergic and sedating effects of triprolidine (confusion, dizziness, urinary retention) and to the cardiovascular stimulant effects of pseudoephedrine; use the lowest effective dose and monitor closely, particularly in those with cardiovascular disease, hypertension, or prostatic hypertrophy.

Hepatic/renal impairment: Use with caution, as reduced clearance may increase systemic exposure and the risk of adverse effects; dose reduction or physician guidance is advised.

A-Cof is intended for short-term, symptomatic use only, typically not exceeding 7 days. If cough or cold/allergy symptoms persist beyond 7 days, recur, or are accompanied by fever, rash, or persistent headache, stop use and consult a physician, as this may indicate a condition requiring different treatment.

Antitussive + Nasal Decongestant + First-generation (sedating) Antihistamine (combination cough and cold preparation)

Dextromethorphan + Pseudoephedrine + Triprolidine works through three complementary mechanisms: dextromethorphan suppresses the cough reflex by acting on the cough center in the brainstem; pseudoephedrine constricts dilated nasal blood vessels via alpha-adrenergic stimulation to relieve congestion; and triprolidine blocks histamine H1 receptors to reduce sneezing, itching, and watery rhinorrhea associated with allergic and cold symptoms.

A-Cof is not recommended for children under 2 years of age because of the risk of serious adverse effects, including fatal overdose, associated with cough and cold combination medicines in this age group. For children 2-6 years, use only under a physician's direct supervision. For children 6-12 years, use only the pediatric dose specified on the product label and do not exceed 4 doses in 24 hours. Keep the product out of the reach of children at all times, as accidental ingestion can be dangerous.